Figure 6.
AEs of clinical interest for ibrutinib-treated patients. Any-grade AEs of clinical interest are shown by yearly interval. Prevalence was determined by the proportion of patients with a given AE (existing event or new onset of an event) during each yearly interval. Multiple onsets of the same AE term within a specific yearly interval were counted once, and the same AE term continuing across several yearly intervals was counted in each of the intervals. aCombined terms.